Skip to main content
. 2024 Nov 20;12(11):e010006. doi: 10.1136/jitc-2024-010006

Table 3. Summary of confirmed tumor response per RECIST V.1.1 by investigator assessment.

IO-108 monotherapyN=12 IO-108+pembrolizumabN=13
Efficacy evaluable, n 11 12+1 crossover
ORR (%) 1 (9.1) 3 (23.1)
DCR (%) 5 (45.5) 7 (53.9)
CR 1 (9.1) 0 (0)
PR 0 (0) 3 (23.1)
SD 4 (36.4) 4 (30.8)
PD 6 (54.5) 6 (46.1)
Not evaluable 1 1

CRcomplete responseDCR, disease control rateORRobjective response ratePDdisease progressionPRpartial responseRECISTResponse Evaluation Criteria In Solid TumorsSDstable disease